(Q34327218)

1 August 2017

title

Acute myeloid leukaemia in adults (English)

1 reference

1 August 2017

1 reference

Felicetto Ferrara

1

1 reference

1 August 2017

Charles A Schiffer

series ordinal

2

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 February 2013

1 reference

1 August 2017

1 reference

1 August 2017

volume

381

1 reference

1 August 2017

issue

9865

1 reference

1 August 2017

page(s)

484-495

1 reference

Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Cytogenetics, Not Just Previous Therapy, Determines the Course of Therapy-Related Myeloid Neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Targeting DNA repair pathways in AML.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Molecular genetics in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

The molecular basis of leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Stem cell gene expression programs influence clinical outcome in human leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Clonal architecture of secondary acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

The prognostic and functional role of microRNAs in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: ...

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

DNMT3A Mutations in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Acute myeloid leukemia stem cells: seek and destroy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Epigenetic mechanisms in AML - a target for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

1 reference

7 January 2021

Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Clinically useful prognostic factors in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

High-dose daunorubicin in older patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

The outcomes and costs of acute myeloid leukemia among the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Acute myeloid leukemia in the real world: why population-based registries are needed

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Haematological cancer: The rule of three in AML induction--is cladribine the answer?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

The clinical development of FLT3 inhibitors in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

FLT3 as a therapeutic target in AML: still challenging after all these years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Anthracycline dose intensification in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Consolidation therapy: what should be the standard of care?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

New agents for acute myeloid leukemia: is it time for targeted therapies?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Reduced mortality after allogeneic hematopoietic-cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Who should be transplanted in first remission of acute myeloid leukaemia?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Modern approaches to treating acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Has there been progress in the treatment of older patients with acute myeloid leukemia?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Treatment of older patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

"I am older, not elderly," said the patient with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Treatment of unfit patients with acute myeloid leukemia: a still open clinical challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Feasibility of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Hypomethylating agents for the treatment of acute myeloid leukemia in the elderly: for all, none, or which patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Prognostic index for adult patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Management of refractory acute myeloid leukemia: re-induction therapy or straight to transplantation?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Very late recurrences of leukemia: why does leukemia awake after many years of dormancy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961727-9

7 January 2021

10.1016/S0140-6736(12)61727-9

Identifiers

DOI

1 reference

1 August 2017

1 reference